Document is current
Any future updates will be listed below
-
Authors
Buse, John B https://orcid.org/0000-0002-9723-3876
Bode, Bruce W
Mertens, Ann
Cho, Young Min
Christiansen, Erik
Hertz, Christin L
Nielsen, Morten A
Pieber, Thomas R
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02849080 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
https://doi.org/10.1136/bmjdrc-2020-001649
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
https://doi.org/10.1007/s13300-020-00994-9
983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7
https://doi.org/10.2337/db19-983-p
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S (N/A)
- License Information
